Guañabens, N. http://orcid.org/0000-0002-7103-9530
Olmos, J. M.
Hernández, J. L.
Cerdà, D.
Hidalgo Calleja, C.
Martinez López, J. A.
Arboleya, L.
Aguilar del Rey, F. J.
Martinez Pardo, S.
Ros Vilamajó, I.
Suris Armangué, X.
Grados, D.
Beltrán Audera, C.
Suero-Rosario, E.
Gómez Gracia, I.
Salmoral Chamizo, A.
Martín-Esteve, I.
Florez, H.
Naranjo, A.
Castañeda, S.
Ojeda Bruno, S.
García Carazo, S.
García Vadillo, A.
López Vives, L.
Martínez-Ferrer, À.
Borrell Paños, H.
Aguado Acín, P.
Castellanos-Moreira, R.
Tebé, C.
Gómez-Vaquero, C.
,
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00762)
Article History
Received: 23 September 2020
Accepted: 4 January 2021
First Online: 18 January 2021
Compliance with ethical standards
:
: Dr. Guañabens has in the past received fees for lectures and/or advice from Alexion, Amgen, Eli Lilly and UCB. Dr. Olmos has received in the past fees for lectures from Amgen, Eli Lilly, Stada and Gedeon-Richter. Dr. Hernandez received grant funding and fees for lectures from AMGEN and MSD. Dr. Naranjo has in the past received fees for lectures and/or advice from Amgen and UCB. Dr. Castañeda has received fees for lectures and/or advice from Amgen, Eli Lilly, MSD, Novartis, Roche, Stada and UCB. Dr. Castellanos-Moreira has in the past received fees for lectures and/or advice from Pfizer, Lilly, UCB and BMS. The remaining authors have no competing interests to disclose.
: The study was approved by the Ethics Committee of the University Hospital of Bellvitge, Catalonia, Spain.
: All RA patients provided a written informed consent to participate.